Detalhe da pesquisa
1.
Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells.
Molecules
; 27(22)2022 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36431901
2.
Role of interferon regulatory factor 1 in governing Treg depletion, Th1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide.
Int J Cancer
; 142(5): 976-987, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28975621
3.
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
J Transl Med
; 13: 139, 2015 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-25933939
4.
Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha.
Front Oncol
; 13: 1145667, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37274275
5.
Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy.
Front Immunol
; 11: 582744, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33193392
6.
Nicotinamide inhibits melanoma in vitro and in vivo.
J Exp Clin Cancer Res
; 39(1): 211, 2020 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33028392
7.
Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study.
Front Oncol
; 10: 202, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32211314
8.
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients.
Int J Cancer
; 124(1): 130-9, 2009 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18839429
9.
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Clin Cancer Res
; 13(2 Pt 1): 644-53, 2007 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17255288
10.
Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.
Cancer Immunol Res
; 6(6): 658-670, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29622580
11.
The added value of type I interferons to cytotoxic treatments of cancer.
Cytokine Growth Factor Rev
; 36: 89-97, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28693974
12.
Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy.
Clin Cancer Res
; 9(6): 2022-31, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12796364
13.
Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.
Cytokine Growth Factor Rev
; 26(2): 121-31, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25578520
14.
Identification of tissue-restricted transcripts in human islets.
Endocrinology
; 145(10): 4513-21, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15231694
15.
Administration of different antigenic forms of altered peptide ligands derived from HIV-1 RTase influences their effects on T helper cell activation.
Hum Immunol
; 64(1): 1-8, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12507809
16.
Shifting gene expression profiles during ex vivo culture of renal tumor cells: implications for cancer immunotherapy.
Oncol Res
; 14(3): 133-45, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14760862
17.
The Janus face of cyclophosphamide: A sterile inflammatory response that potentiates cancer immunotherapy.
Oncoimmunology
; 2(9): e25789, 2013 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24244905
18.
Exploiting dendritic cells in the development of cancer vaccines.
Expert Rev Vaccines
; 12(10): 1195-210, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24090117
19.
Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy.
Clin Cancer Res
; 19(15): 4249-61, 2013 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23759676
20.
Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.
Mol Oncol
; 6(1): 1-14, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22177803